Return to search results.
Complete title: A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory B Cell Malignancies
|Research Study Number||2669.00|
|Principal Investigator||Bill Bensinger, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Hematologic Malignancies; Lymphoma; Multiple Myeloma (MM)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.